Supplementary Figures 1-8 from Targeting Unc51-like Autophagy Activating Kinase 1 (ULK1) Overcomes Adaptive Drug Resistance in Acute Myelogenous Leukemia

S1. Effect of genetic abrogation of ULK1 in vitro and in vivo. S2. ULK1 inhibitor SBI-0206965 has anti-leukemic activity and can overcome autophagic adaptation in drug-resistant cells. S3. ULK1 inhibition reverses drug-resistance and synergizes with AML therapies. S4. ULK1 inhibition changes signaling in AML cells. S5. ULK1 inhibition hampers ROS. S6. ULK1 inhibition accumulates dysfunctional mitochondria. S7. ULK1 inhibition impairs colony forming ability and delays leukemia progression. S8. In vitro and in vivo synergy of ULK1 inhibition with AML therapies.